Sorafenib Tosylate

Sorafenib (BAY 43-9006) is a dual-action multikinase inhibitor that targets both the RAF/MEK/ERK signaling pathway in tumor cells and receptor tyrosine kinases involved in tumor angiogenesis. In biochemical assays, sorafenib inhibits Raf-1 with an IC50 of 6 nM and wild-type B-Raf with an IC50 of 22 nM. The compound also blocks the activity of vascular endothelial growth factor receptors VEGFR-2 and VEGFR-3 with IC50 values of 90 nM and 15 nM respectively, as well as PDGFR-β, Flt-3, and c-KIT.
In cellular systems, sorafenib treatment results in dose-dependent inhibition of MEK and ERK phosphorylation across multiple cancer cell lines. This dual mechanism simultaneously disrupts tumor cell proliferation through MAPK pathway blockade and inhibits neovascularization by suppressing VEGF and PDGF signaling. Oral administration of sorafenib produces broad-spectrum antitumor activity in human tumor xenograft models, including colon, breast, and non-small cell lung carcinomas.

Fig. 1 Inhibition of HT-29 tumor growth and the MAPK pathway by BAY 43–9006. (Wilhelm S M.; et al. 2004)

Hyaluronic acid-coated chitosan nanoparticles loaded with sorafenib tosylate were developed for targeted hepatocellular carcinoma therapy using a Box-Behnken design optimization approach. The optimal formulation achieved a particle size of 147.43 nm, entrapment efficiency of 66.40 percent, and zeta potential of -11.08 mV. Drug release followed the Higuchi model with Fickian diffusion characteristics. In vitro cytotoxicity assays on HepG2 cells demonstrated significantly greater anti-cancer activity compared to free sorafenib. In vivo studies in Wistar rats confirmed superior biocompatibility, targeting efficiency, and improved pharmacokinetic profiles of the nanoparticle formulation.

Fig. 2 Hyaluronic acid-coated chitosan nanoparticles loaded with Sorafenib Tosylate for hepatocellular carcinoma. (Sreelaya P.; et al. 2025)